What's in Xanthus Pharmaceuticals, Inc.'s pipeline?

Xanthus Pharmaceuticals, Inc. has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Xanthus Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, DEKK-TEC, Inc., Italian Sarcoma Group, PETHEMA Foundation, The University of Hong Kong.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/xanthus-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Xanthus Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Xanthus Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
DEKK-TEC, Inc. · 1 shared drug class
Italian Sarcoma Group · 1 shared drug class
PETHEMA Foundation · 1 shared drug class
The University of Hong Kong · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Xanthus Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Xanthus Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xanthus-pharmaceuticals-inc. Accessed 2026-05-16.